Amneal Pharmaceuticals
AMRX
182 hedge funds and large institutions have $1.18B invested in Amneal Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 65 increasing their positions, 57 reducing their positions, and 25 closing their positions.
35% more capital invested
Capital invested by funds: $874M → $1.18B (+$306M)
26% more call options, than puts
Call options by funds: $609K | Put options by funds: $483K
14% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 57
1.21% more ownership
Funds ownership: 44.57% → 45.78% (+1.2%)
4% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 25
1% more funds holding
Funds holding: 181 → 182 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$12.3M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$9.93M |
| 3 |
BlackRock
New York
|
+$8.82M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$8.75M |
| 5 |
JP Morgan Chase
New York
|
+$6.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
-$22.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$8.57M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$6.71M |
| 4 |
Goldman Sachs
New York
|
-$4.12M |
| 5 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$3.6M |
AMRX Hedge Fund Activity: Q3 2024 in Review
182 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q3 2024, worth a combined $1.18B — up 35% from $874M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new AMRX positions and 25 closed out — a net gain of 1 holder — while 65 added to existing stakes and 57 trimmed.
The largest buyer was Ameriprise, adding an estimated $12.3M. The largest seller was Fosun International, cutting an estimated $22.9M.
- 182 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q3 2024, up from 181 in Q2 2024.
- Funds reported $1.18B of Amneal Pharmaceuticals stock for Q3 2024, up 35% quarter-over-quarter.
- 26 funds opened new Amneal Pharmaceuticals positions in Q3 2024 and 25 closed out, a net change of +1 holder.
- The largest Amneal Pharmaceuticals buyer in Q3 2024 was Ameriprise, an estimated $12.3M added.
- The largest Amneal Pharmaceuticals seller in Q3 2024 was Fosun International, an estimated $22.9M sold.
Based on aggregated 13F filings for Q3 2024.